Development Pipeline
Development pipeline (as of July 26, 2018)
Development Pipeline [
211KB]
211KB]Oncology
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG7446 (MPDL3280A) |
Non-small cell lung cancer (NSCLC) [2nd line] |
Launched (18/04) |
atezolizumab Tecentriq® Injection |
Roche Tecentriq® |
Engineered anti-PDL1 monoclonal antibody |
| NSCLC [1st line] # |
Filed (18/03) |
||||
| NSCLC (adjuvant) # |
Phase III Multinational study |
||||
| Small cell lung cancer # |
Phase III Multinational study |
||||
| Urothelial carcinoma # |
Phase III Multinational study |
||||
| Muscle invasive urothelial carcinoma (adjuvant) # |
Phase III Multinational study |
||||
| Renal cell carcinoma # |
Phase III Multinational study |
||||
| Renal cell carcinoma (adjuvant) # |
Phase III Multinational study |
||||
| Breast cancer # |
Phase III Multinational study |
||||
| Ovarian cancer # |
Phase III Multinational study |
||||
| Prostate cancer # |
Phase III Multinational study |
||||
| Hepatocellular carcinoma # |
Phase III Multinational study |
||||
| Head and neck carcinoma (adjuvant) # |
Phase III Multinational study |
||||
| GA101/RG7159 (RO5072759) |
Follicular lymphoma |
Approved (18/07) |
obinutuzumab Gazyva® Injection |
Roche Gazyva®/ Gazyvaro® (EU) (Nippon Shinyaku) |
Glycoengineered type II anti-CD20 monoclonal antibody |
| RG1273 (RO4368451) |
Breast cancer (adjuvant) # |
Filed (17/10) |
pertuzumab Perjeta® Injection |
Roche Perjeta® |
HER2 dimerization inhibitory humanized monoclonal antibody |
| RG435 (RO4876646) |
Renal cell carcinoma # |
Phase III Multinational study |
bevacizumab Avastin® Injection |
Roche Avastin® |
Anti-VEGF (Vascular Endothelial Growth Factor) humanized monoclonal antibody |
| Hepatocellular carcinoma # |
Phase III Multinational study |
||||
| RG3502 (RO5304020) |
Breast cancer (adjuvant) # |
Phase III Multinational study |
trastuzumab emtansine Kadcyla® Injection |
Roche Kadcyla® |
Anti-HER2 antibody-tubulin polymerization inhibitor conjugate |
| RG7440 (GDC-0068) |
Prostate cancer | Phase III Multinational study |
ipatasertib Oral |
Roche/Array BioPharma | AKT inhibitor |
| Breast cancer | Phase III Multinational study |
||||
| RG7596 (RO5541077) |
Diffuse large B-cell lymphoma (DLBCL) |
Phase III Multinational study |
polatuzumab vedotin Injection |
Roche | Anti-CD79b antibody-drug conjugate |
| RG6264 (RO7198574) |
Breast cancer (Fixed-dose combination, subcutaneous injection) |
Phase III Multinational study |
trastuzumab/pertuzumab Herceptin®/ Perjeta® Injection |
Roche Herceptin®/Perjeta® |
Anti-HER2 humanized monoclonal antibody/ HER2 dimerization inhibitory humanized monoclonal antibody |
| RG6268 (RXDX-101) |
NSCLC | Phase III Multinational study |
entrectinib Oral |
Roche/ Nerviano Medical Sciences |
ROS1/TRK inhibitor |
| Solid tumors | |||||
| GC33/RG7686 (GC33/ RO5137382) |
Hepatocellular carcinoma | Phase I Multinational study* |
codrituzumab Injection |
In-house (Roche) |
Anti-Glypican-3 humanized monoclonal antibody |
| CKI27 (CKI27) |
Solid tumors | Phase I | Oral |
In-house |
Raf and MEK dual inhibitor |
| Phase I Overseas |
|||||
| ERY974 (ERY974) |
Solid tumors | Phase I Overseas |
Injection |
In-house | Anti-Glypican-3/CD3 bispecific antibody |
| RG7421 (GDC-0973) |
Solid tumors | Phase I | cobimetinib Oral |
Roche/Exelixis Cotellic® |
MEK inhibitor |
| RG7802 (RO6958688) |
Solid tumors | Phase I | Injection |
Roche | Anti-CEA/CD3 bispecific antibody |
| RG7828 (RO7030816) |
Hematologic tumors | Phase I | Injection |
Roche | Anti-CD20/CD3 bispecific antibody |
| RG7604 (GDC-0032) |
Solid tumors | Development discontinued | taselisib Oral |
Roche | PI3K inhibitor |
* Multinational studies managed by Chugai
Bone and Joint Diseases
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| ED-71 (ED-71) |
Osteoporosis |
Filed (18/02) China |
eldecalcitol Edirol® Oral |
In-house | Activated vitamin D3 agent |
| NRD101 (NRD101) |
Knee osteoarthritis /Shoulder periarthritis |
Phase III China |
purified sodium hyaluronate Suvenyl® Injection |
In-house | Sodium hyaluronate |
Renal Diseases
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| EOS789 (EOS789) |
Hyperphosphatemia | Phase I | Oral |
In-house | ‒ |
| Phase I Overseas |
Autoimmune Diseases
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| MRA/RG1569 (RO4877533) |
Systemic sclerosis # |
Phase III Multinational study |
tocilizumab Actemra® Injection |
In-house Actemra®/ RoActemra® (EU) (Roche) |
Humanized anti-human IL-6 receptor monoclonal antibody |
| SA237/RG6168 (SA237) |
Neuromyelitis optica (NMO) | Phase III Multinational study* |
satralizumab Injection |
In-house (Roche) |
Anti-IL-6 receptor recycling antibody |
| RG7845 (GDC-0853) |
Rheumatoid arthritis | Phase I | fenebrutinib Oral |
Roche |
BTK inhibitor |
* Multinational studies managed by Chugai
Neurology
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| RG1450 (RO4909832) |
Alzheimer’s disease | Phase III Multinational study |
gantenerumab Injection |
Roche/MorphoSys | Anti-amyloid-beta human monoclonal antibody |
| RG7412 (RO5490245) |
Alzheimer’s disease | Phase III Multinational study |
crenezumab Injection |
Roche/AC Immune | Anti-amyloid-beta humanized monoclonal antibody |
| RG6206 (BMS-986089) |
Duchenne muscular dystrophy (DMD) | Phase II/III Multinational study |
Injection |
Roche/Bristol-Myers Squibb | Anti-myostatin adnectin |
| RG7916 (RO7034067) |
Spinal muscular atrophy (SMA) | Phase II Multinational study |
risdiplam Oral |
Roche/PTC Therapeutics | SMN2 splicing modifier |
| RG7935 (RO7046015) |
Parkinson’s disease | Phase I | prasinezumab Injection |
Roche/Prothena | Anti-α-synuclein monoclonal antibody |
Others
| Development code (Compound number) |
Indication # Additional indication |
Stage (Date) |
Generic name Product name Dosage form |
Origin Overseas name (Collaborator) |
Mode of Action |
|---|---|---|---|---|---|
| ACE910/RG6013 (RO5534262) |
Hemophilia A (Inhibitor) |
Launched (18/05) Japan |
emicizumab Hemlibra® Injection |
In-house Hemlibra® (Roche) |
Anti-FIXa/FX bispecific antibody |
| Approved (18/02) Europe |
|||||
| Hemophilia A (Non-inhibitor) |
Filed (18/04) Japan |
||||
|
Filed (18/04) US/Europe |
|||||
| CIM331** (CIM331) |
Pruritus in dialysis patients | Phase II | nemolizumab Injection |
In-house |
Anti-IL-31 receptor A humanized monoclonal antibody |
| SKY59/RG6107 (RO7112689) |
Paroxysmal nocturnal hemoglobinuria (PNH) |
Phase I/II Multinational study |
Injection |
In-house (Roche) |
Anti-C5 recycling antibody |
| PCO371 (PCO371) |
Hypoparathyroidism | Phase I Overseas |
Oral |
In-house | PTH1 receptor agonist |
| RG7716 (RO6867461) |
Wet age-related macular degeneration / Diabetic macular edema | Phase I |
Injection |
Roche | Anti-VEFG/Ang2 bispecific antibody |
| AMY109 | Endometriosis | Phase I |
Injection |
In-house | ‒ |
| URC102 (URC102) |
Gout |
Development discontinued |
Oral |
In-house/JW Pharmaceutical (JW Pharmaceutical) |
URAT1 inhibitor |
** Development for atopic dermatitis: Out-licensed to Galderma (Overseas) and Maruho (Japan)
In principle, completion of first dose is regarded as the start of clinical studies in each phase.
IFRS References
ESG References
To view PDF files,
you will need Adobe® Reader® which is available as a free download.